
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics Inc is experiencing robust growth in its Filspari prescribing, with a notable increase in new patient start forms by 37% quarter-over-quarter in the fourth quarter of 2024. The company is positioned for significant market expansion with its ongoing regulatory initiatives, including a supplemental new drug application for Filspari targeting focal segmental glomerulosclerosis (FSGS), projected to contribute to a sizable market opportunity of approximately $521 million by 2030. Additionally, improvements in gross-to-net discounts, alongside favorable physician insights suggesting rapid uptake in FSGS for Filspari, indicate a strong potential for continued revenue momentum and overall positive market reception.
Bears say
The financial outlook for Travere Therapeutics Inc appears negative due to significant commercial risks associated with its pipeline product, Filspari. The company's survey indicates that a majority of IgAN patients fall below the crucial threshold for the growth driver, potentially limiting Filspari's market penetration. Furthermore, increasing competition in the market, along with the possibility of generic entry and the presence of drugs with superior efficacy or safety profiles, raises concerns about Travere's ability to meet revenue expectations in both IgAN and FSGS indications.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares